We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says
PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says
August 10, 2012
A new study shows the U.S. outpaces Europe in approving new cancer drugs, but that lead could be in jeopardy under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), an expert tells IPRM.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor